PAIP2

Across TCGA pan-cancer cohorts, PAIP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PAIP2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PAIP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PAIP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

GBM, HNSC, and OV are the cancer types where PAIP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.258	0.431	.003	28	view →
HNSC	DFS	Median	III,IV	0.749	0.518	.016	23	view →
OV	DFS	Median	All	0.863	1.000	.033	20	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PAIP2–GBM (DFS)

Open the GBM breakdown →